Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease por Keshav, S, Ungashe, S, Zheng, W, Belker, P, Wright, K, Schall, T

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease por Bekker, P, Keshav, S, Wei, Z, Ertl, L, Wang, Y, Lai, N, Wright, J, Ungashe, S, Schall, T

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease por Bekker, P, Velde, A, Pronk, I, Keshav, S, Hommes, D, Hanauer, S, Ungashe, S, Zheng, W, Wright, K, Schall, T

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. por Walters, M, Wang, Y, Lai, N, Baumgart, T, Zhao, B, Dairaghi, D, Bekker, P, Ertl, L, Penfold, M, Jaen, J, Keshav, S, Wendt, E, Pennell, A, Ungashe, S, Wei, Z, Wright, J, Schall, T

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B por Ungashe, S, Wei, Z, Rubas, W, Lai, N, Ertl, L, Baumgart, T, Wang, H, Miao, Z, Hor, S, Premack, B, Moore, J, Sullivan, E, Pennell, A, Keshav, S, Sanders, M, Howard, M, Wright, J, Bekker, P, Schall, T